vs
Side-by-side financial comparison of Hyperliquid Strategies Inc (PURR) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
China SXT Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($829.5K vs $500.0K, roughly 1.7× Hyperliquid Strategies Inc). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -60892.6%, a 60795.8% gap on every dollar of revenue.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
PURR vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $500.0K | $829.5K |
| Net Profit | $-304.5M | $-802.6K |
| Gross Margin | — | 16.2% |
| Operating Margin | -57509.2% | -76.9% |
| Net Margin | -60892.6% | -96.8% |
| Revenue YoY | — | 0.0% |
| Net Profit YoY | — | 0.0% |
| EPS (diluted) | $-7.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $500.0K | — | ||
| Q3 25 | — | $829.5K | ||
| Q3 24 | — | $829.5K | ||
| Q3 23 | — | $939.6K | ||
| Q3 22 | — | $1.2M | ||
| Q3 21 | — | $1.0M |
| Q4 25 | $-304.5M | — | ||
| Q3 25 | — | $-802.6K | ||
| Q3 24 | — | $-802.6K | ||
| Q3 23 | — | $-9.7M | ||
| Q3 22 | — | $-1.5M | ||
| Q3 21 | — | $-3.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 16.2% | ||
| Q3 24 | — | 16.2% | ||
| Q3 23 | — | 30.7% | ||
| Q3 22 | — | 7.4% | ||
| Q3 21 | — | 31.5% |
| Q4 25 | -57509.2% | — | ||
| Q3 25 | — | -76.9% | ||
| Q3 24 | — | -76.9% | ||
| Q3 23 | — | -995.0% | ||
| Q3 22 | — | -95.2% | ||
| Q3 21 | — | -281.4% |
| Q4 25 | -60892.6% | — | ||
| Q3 25 | — | -96.8% | ||
| Q3 24 | — | -96.8% | ||
| Q3 23 | — | -1032.0% | ||
| Q3 22 | — | -123.7% | ||
| Q3 21 | — | -300.9% |
| Q4 25 | $-7.43 | — | ||
| Q3 25 | — | — | ||
| Q3 24 | — | $-0.25 | ||
| Q3 23 | — | $-19.34 | ||
| Q3 22 | — | $-14.61 | ||
| Q3 21 | — | $-3.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $281.9M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $589.8M | $15.4M |
| Total Assets | $616.6M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $281.9M | — | ||
| Q3 25 | — | $18.1M | ||
| Q3 24 | — | $18.5M | ||
| Q3 23 | — | $11.5M | ||
| Q3 22 | — | $3.0M | ||
| Q3 21 | — | $31.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | $105.0K | ||
| Q3 24 | — | $952.3K | ||
| Q3 23 | — | $106.6K | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
| Q4 25 | $589.8M | — | ||
| Q3 25 | — | $15.4M | ||
| Q3 24 | — | $15.0M | ||
| Q3 23 | — | $5.1M | ||
| Q3 22 | — | $14.5M | ||
| Q3 21 | — | $13.8M |
| Q4 25 | $616.6M | — | ||
| Q3 25 | — | $21.7M | ||
| Q3 24 | — | $31.0M | ||
| Q3 23 | — | $14.6M | ||
| Q3 22 | — | $22.2M | ||
| Q3 21 | — | $22.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.01× | ||
| Q3 24 | — | 0.06× | ||
| Q3 23 | — | 0.02× | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.4M |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -216.2% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.4M | ||
| Q3 24 | — | $-1.4M | ||
| Q3 23 | — | $-579.6K | ||
| Q3 22 | — | $-549.1K | ||
| Q3 21 | — | $-312.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.8M | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -216.2% | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.9% | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — | ||
| Q3 21 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
